Compositions and uses of humoral immunosuppression antagonists for treating humoral immunosuppression diseases

By developing a fusion protein containing MCB domain and ankyrin, the problem of CA125 protein inhibiting humoral immune response was solved, and the antibody-mediated humoral immune response and therapeutic effect was significantly improved.

CN114269791BActive Publication Date: 2024-11-29NAVROGEN INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202080055914.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-08-06
Publication Date
2024-11-29
Estimated Expiration
2040-08-06

AI Technical Summary

Technical Problem

Tumors inhibit humoral immune response through CA125 protein, resulting in poor antibody-mediated treatment effects, and the prior art is difficult to effectively overcome this immunosuppression.

Method used

A fusion protein is developed that contains at least two mesothelins with minimal CA125 binding domains (MCB domains) and ankyrins to block the immunosuppression of CA125 and enhance antibody-mediated humoral immune response.

Benefits of technology

It significantly improves the antibody-mediated humoral immune response, enhances the killing ability of tumor cells, overcomes the immunosuppression caused by CA125 protein, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114269791B_ABST
    Figure CN114269791B_ABST
Patent Text Reader

Abstract

The CA125 / MUC16 protein has been found to be an inhibitor of humoral immunity, particularly an inhibitor of antibody-mediated humoral immunity. The generation of antagonists that can block its immunosuppressive effects on antibodies can lead to enhanced therapeutic responses of antibodies that are adversely affected by CA125 / MUC16. In addition, it also provides the ability to relieve humoral immunosuppression of endogenous humoral responses of patients that may be suppressed by CA125 / MUC16 inhibition. CA125 / MUC16 antagonists can be used to enhance the humoral response of therapeutic antibodies and patients with CA125 / MUC16 expressing diseases (including cancer).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of humoral immunity and humoral immuno-oncology. Specifically, it relates to methods, kits and pharmaceutical compositions that can block and inhibit the immunosuppressive effects of CA125 / MUC16 proteins to improve the efficacy of antibody-based treatments in inhibiting cancer growth and other humoral immunosuppressive diseases. Background Art

[0002] Humoral immunity is the main mechanism for vertebrate host biological surveillance and defense against infectious pathogens and host cell disorders. In cancer biology, immune checkpoint inhibitors that overcome suppressed cell-mediated immunity show a strong effect in releasing activated CD8+T cells to kill tumor subsets (Hodi FS, et al. N Engl J Med 363: 711-723, 2010). It is reported that several commercially approved therapeutic antibodies show their pathogen and / or tumor killing effects through humoral-mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (DiLillo DJ, Ravetech JV, Cancer Immunol Res 3: 704-713, 2015; Ruck T, et al. Int J Mol Sci. 16: 16414–16439, 2015; Pelaia C, et al. Biomed Res Int 4839230: 1-9, 2018). Recent translational studies have found that tumors use factors that can inhibit humoral immune pathways, thereby inhibiting the tumor killing effects of ADCC and CDC (VergoteI, et al. J Clin Oncol 34: 2271-2278; Kline JB, et al. J Clin Oncol 5: 15, 2018; WangW et al. Cytogenet Genome Res 152: 169-179, 2017; Kline JB et al. Eur J Immunol. 48: 1872-1882, 2018). Antibody-mediated humoral immune responses are coordinated by antibody-cell surface antigen binding, which in turn positions the antibody on the antigen epitope to a certain extent close to the cell surface. In this optimally positioned case, cell surface-bound antibodies can bind to Fc-γ activating receptors on natural killer (NK) or dendritic / myeloid / monocytes (any cell involved in ADCC is referred to as an "immune effector cell" herein) to initiate ADCC and bind to the C1q complement activating protein to cause the death of the antibody-bound cell through the classical complement CDC pathway (Reuschenbach M, et al. Cancer Immunol Immunother 58: 1535-1544, 2009).These effects have been observed during the development of several therapeutic antibodies, such as but not limited to rituximab, trastuzumab, cetuximab, alemtuzumab, and many experimental antibodies (Zhou X, et al. Oncologist 13:954-966, 2008; Hsu YF, et al. Mol Cancer 9:-8, 2010; Spiridon CI, et al. Clin Cancer Res 8:1720-1730, 2002; Kline JB, et al. Eur J Immunol 48:1872-1882, 2018). Similarly, humoral effects have been shown to occur in the patient's own immune response to dysregulated cells in response to vaccines and in people with indolent disease, where antibodies produced are primarily of the IgM class, with antiproliferative and immune-mediated killing activity (Staff C, et al. J Clin Immunol 32: 855-865; Branden S, et al. Cancer Res 63: 7995-8005, 2003). However, although many cancer patients have been found to produce autoantibodies against tumor-expressed antigens, their presence is insufficient to control tumor growth, which may be due to overall antibody levels and / or humoral immune suppression mechanisms.

[0003] Some reports have found that the tumor-produced protein MUC16 / CA125 can inhibit humoral immune responses by directly binding to negative immunoregulatory receptors of the SIGLEC family to inhibit NK cell activation (Belisle JA, et al. Mol Cancer 9:1476-4598, 2010) and by directly binding to a subset of IgG1, IgG3, and IgM antibodies, which in turn disrupts the Fc region, making IgG1 and IgG3 antibodies less efficient at binding to the Fc-γ activating receptors FCGR2A (also known as CD32a) and FCGR3A (also known as CD16a) on immune effector cells and / or all three antibody classes less efficient at binding to complement-mediating proteins, including C1q (Pantankar MS, et al. Gyncol Oncol 99:704-713, 2005; Kline JB, et al. OncoTarget 8:52045-52060, 2017; Kline JB, et al. al.J.Clin.Oncol.5:15,2018;Wang W,et al.Cytogenet Genome Res 152:169-179,2017;Kline JB,et al.Eur JImmunol.48:1872-1882,2018). These include clinical studies of anticancer antibodies whose pharmacological activity relies on immune effector mechanisms, in which serum CA125 levels were found to be associated with clinical outcomes. These include reports on experimental farletuzumab antibodies in ovarian cancer and amatuximab antibodies in mesothelioma (Vergote I,et al.J Clin Oncol 34:2271-2278,2016;Nicolaides NC,et al.Cancer Biol Ther 13:1-22,2018) and commercially approved rituximab antibodies for patients with Hodgkin and non-Hodgkin lymphoma. Among them, rituximab plus CHOP (cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine In a study published in the journal Cell Biology, patients with follicular lymphoma treated with 100 mg / mL and prednisolone (100 mg / mL) had a 31.4% improvement in 5-year PFS when CA125 levels were within the normal range (Prochazka V, et al. Int J Hematol 96:58-64, 2012), in contrast to those patients with statistically significant worse clinical outcomes above the normal range. Based on these findings, there is a continuing need in the art to develop tools and agents that can overcome humoral immune suppression mediated by such proteins and other similar proteins in cancer patients and diseases in which humoral immune suppression is active due to the presence of CA125 / MUC16 (referred to herein as CA125).

[0004] Recent publications indicate that mesothelin is a cell surface protein that is expressed by several tumor types and can bind to the CA125 protein. Both mesothelin and CA125 have been found to be membrane-bound as well as soluble. Their interaction may occur as two soluble factors, two membrane-bound factors that mediate heterotypic cell adhesion, and / or as membrane-bound forms that can interact with soluble forms of other proteins (Rump A, et al. J Biol Chem 279: 9190-9198, 2004; Hassan R, et al. Cancer Immunol 7: 20-30, 2007; Kaneko O, et al. J Biol Chem 284: 3739-3749, 2009; Hassan R. Lung Cancer 68: 455-459, 2010). The CA125 binding domain within the mesothelin protein has been mapped to the amino acid region 296-359 and has been shown to be sufficient to bind to membrane-bound CA125 when fused to the IgG Fc heavy chain (called HN125) or domains of other proteins such as the death receptor binding domain of the TRAIL protein (called Meso64-TR3) (Xiang X, et al. J Cancer 2:280-291, 2011; Su Y, et al. OncoTarget 7:31534-31549, 2016). Summary of the invention

[0005] One aspect of the invention is a fusion protein comprising at least two copies of the minimal CA125 binding (MCB) domain of mesothelin, as shown in SEQ ID NO: 1. The MCB domain comprises amino acids 296 to 359 of mesothelin. The fusion protein further comprises an ankyrin. If it is a monomer, the fusion protein and / or the ankyrin is at least 60 kDa, if it is a polymer, it is at least 30 kDa.

[0006] Another aspect of the present invention is a nucleic acid vector encoding an MCB domain fusion protein. The fusion protein comprises at least two copies of the minimal CA125 binding (MCB) domain of mesothelin, as shown in SEQ ID NO: 1. The MCB domain comprises amino acids 296 to 359 of mesothelin. The fusion protein further comprises an anchor protein. If it is a monomer, the fusion protein and / or the anchor protein is at least 60 kDa, if it is a polymer, it is at least 30 kDa.

[0007] Another aspect of the invention is a stable cell line encoding an MCB domain fusion protein. The fusion protein comprises at least two copies of the minimal CA125 binding (MCB) domain of mesothelin, as shown in SEQ ID NO: 1. The MCB domain comprises amino acids 296 to 359 of mesothelin. The fusion protein further comprises an anchor protein. If it is a monomer, the fusion protein and / or the anchor protein is at least 60 kDa, if it is a polymer, it is at least 30 kDa.

[0008] Another aspect of the invention is a method for treating a patient with a disease that expresses elevated levels of CA125 compared to healthy people. An MCB domain fusion protein is administered to the patient. The fusion protein comprises at least two copies of the minimal CA125 binding (MCB) domain of mesothelin, as shown in SEQ ID NO: 1. The MCB domain comprises amino acids 296 to 359 of mesothelin. The fusion protein further comprises an anchor protein. If it is a monomer, the fusion protein and / or anchor protein is at least 60 kDa, and if it is a polymer, it is at least 30 kDa. Alternatively, a conjugate or protein comprising multiple MCB domains can be used.

[0009] Another aspect of the invention is a method for treating a patient with a disease that expresses elevated levels of CA125 compared to healthy people. An antibody is administered to the patient. The antibody (a) targets the tumor and (b) in the absence of the MCB domain fusion protein, the humoral immune response mediated by the antibody is inhibited by CA125. The MCB domain fusion protein is also administered to the patient. The fusion protein comprises at least two copies of the minimal CA125 binding (MCB) domain of mesothelin, as shown in SEQ ID NO:1. The MCB domain comprises amino acids 296 to 359 of mesothelin. The fusion protein further comprises an anchor protein. If it is a monomer, the fusion protein and / or anchor protein is at least 60 kDa, and if it is a polymer, it is at least 30 kDa. Alternatively, a conjugate or protein comprising multiple MCB domains can be used.

[0010] Another aspect of the present invention is a method for monitoring a tumor expressing CA125 in a patient. A bodily fluid sample from a patient is contacted with an MCB domain fusion protein. The fusion protein comprises at least two copies of the minimal CA125 binding (MCB) domain of mesothelin, as shown in SEQ ID NO:1. The MCB domain comprises amino acids 296 to 359 of mesothelin. The fusion protein further comprises an anchor protein. If it is a monomer, the fusion protein and / or anchor protein is at least 60 kDa, and if it is a polymer, it is at least 30 kDA. CA125 bound by the fusion protein is then detected. Alternatively, a conjugate or protein comprising multiple MCB domains can be used.

[0011] Another aspect of the invention is a conjugate comprising a polypeptide comprising at least two copies of the minimal CA125 binding (MCB) domain of mesothelin as shown in SEQ ID NO: 1. The MCB domain comprises amino acids 296 to 359 of mesothelin. The polypeptide consists of at least two copies of the MCB domain linked to an anchoring polymer, wherein the conjugate and / or the anchoring polymer is at least 60 kDa. As discussed above with respect to fusion proteins, the conjugate can be used for treatment or monitoring.

[0012] Another aspect of the invention is a polypeptide comprising at least two copies of the minimal CA125 binding (MCB) domain of mesothelin, as shown in SEQ ID NO: 1. The MCB domain comprises amino acids 296 to 359 of mesothelin. The polypeptide contains at least two copies of the MCB domain and is bound to a liposome. As discussed above with respect to fusion proteins, the polypeptide can be used for treatment or monitoring.

[0013] In one aspect, the mesothelin-Fc fusion protein composition comprises a fusion protein containing two or more mesothelin-CA125 binding domains. The mesothelin binding domain is composed of at least the minimum CA125 binding (MCB) domain of mesothelin (SEQ ID: 1). Two or more such domains can be combined in series or randomly or in other configurations by genetic fusion or chemical connection.

[0014] In another aspect of the present invention, the fusion protein composition consists of two MCB domains (MCB domain-2X) genetically linked to the N-terminus of human Fc IgG1 heavy chain (SEQ ID: 2). The two MCB domains can be linked together by an amino acid spacer.

[0015] In another aspect of the invention, the spacer connecting the two MCB domains is optimized for (a) binding of the fusion protein to CA125 and / or (b) reducing immunosuppression of antibody-mediated humoral responses.

[0016] In yet another aspect of the invention, the fusion protein composition consists of three or more MCB domains genetically linked to the N-terminus of a human Fc IgG1 heavy chain (SEQ ID: 3) using an optimal amino acid spacer for maximizing CA125 binding.

[0017] Another aspect of the present invention is to provide a kit for characterizing the ability of MCB domain fusion proteins to block the immunosuppressive activity of CA125 proteins. The kit comprises a fusion protein consisting of two or more MCB domain binding domains and an anchor protein or scaffold (such as but not limited to a polymer or liposome) consisting of a protein having a molecular size of at least 60 kDa (if a monomer) or a size of at least 30 kDa (if a multimer), and / or a nanoparticle (hereinafter referred to as a "fusion protein"), and any method used by a person skilled in the art is used to test it in vitro to determine whether the fusion protein can remove the binding of CA125 to the affected IgG1, IgG3 or IgM antibody (hereinafter referred to as a "test antibody") and then optimally inhibit the engagement with the Fc-γ receptor CD16a or CD32a and / or C1q complement protein, or remove the activation of the inhibition of NK cells by CA125 binding to the SIGLEC receptor and / or directly binding to the test antibody.

[0018] In another aspect of the invention, the kit is used to determine the ability of the MCB domain fusion protein to remove the humoral inhibitory effect of CA125 on a test antibody, using any method used by those skilled in the art, using a bioassay to measure antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

[0019] In another aspect of the present invention, the kit is used to measure the ability of MCB domain fusion protein to remove the internalization inhibitory effect of CA125 on the test antibody, wherein the test antibody is labeled and uses the method for measuring antibody internalization commonly used by those skilled in the art to monitor its internalization in CA125 expressing cells in the presence or absence of MCB domain fusion protein. Antibody drug conjugates (ADC) can also be used to test the ability of MCB domain fusion protein to monitor internalization, wherein by any method commonly used by those skilled in the art, a method for measuring cell viability as a function of ADC internalization and target cell killing is used. ADC is defined herein as an antibody that directly or indirectly binds to a cytotoxic agent, wherein the cytotoxic agent is an immunotoxin, a chemical toxin or a chemical toxin, an RNA inhibitor or a radionuclide.

[0020] Another aspect of the invention is the use of a fusion protein comprising two or more MCB domains, wherein a patient expressing CA125 is administered the fusion protein as a single agent or in combination with a therapeutic antibody inhibited by CA125, with or without standard of care chemotherapy for cancer indications. CA125 expression is determined using serum analysis or biopsy by methods used by those skilled in the art.

[0021] In yet another aspect of the invention, a fusion protein containing two or more MCB domains is administered in combination with an ADC to a patient expressing CA125, with or without standard of care. CA125 expression is determined using serum analysis or biopsy by methods used by those skilled in the art.

[0022] In another aspect of the invention, a fusion protein containing two or more MCB domains is combined with a therapeutic antibody inhibiting CA125 and administered to a patient with a non-oncology indication with or without standard of care therapy. CA125 expression is determined using serum analysis or biopsy by methods used by those skilled in the art.

[0023] Yet another aspect of the present invention is the use of a fusion protein comprising two or more MCB domains, wherein the fusion protein is labeled with any detection agent known to those skilled in the art, to detect CA125 positive tumors by biopsy or in situ in a patient.

[0024] These and other aspects of the invention that will be apparent to those skilled in the art after reading the specification provide the art with methods, compositions and kits for improving antibody-mediated humoral immune responses and therapeutic responses of ADCs in CA125-expressing diseases, including cancer and non-tumor diseases treated with antibodies whose mechanisms of action include humoral-mediated immune responses. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Schematic diagram of the following fusion proteins: containing two MCB domains (MCB domain-2X) domains (fusion protein A); containing three or more MCB domains (fusion protein B); a fusion protein comprising two MCB domains (MCB domain-2X) domains genetically linked in tandem to a human Fc IgG1 heavy chain including its disulfide bridge portion (SEQ ID NO: 2) via an amino acid spacer (fusion protein C); and a fusion protein comprising at least two MCB domains linked to an ankyrin in a non-tandem structure (fusion protein D). AP represents ankyrin linked to MCB domains; MCB domain (SEQ ID NO: 1) represents a portion of mesothelin that includes at least a minimal CA125 binding domain; Fc represents a human Fc domain of an IgG1 heavy chain including its disulfide bridge portion; SP represents an amino acid spacer linking the MCB domains to each other.

[0026] Figure 2A-2B The binding of an FcIgG1 heavy chain fusion protein comprising one and two or more MCB domains (SEQ ID NO: 1) fused to the N-terminus of the CA125 protein ( Figure 2A). Briefly, 96-well ELISA plates were coated with 15 KU / mL soluble CA125 or human serum albumin (HSA) as a negative control, and CA125 binding was detected by probing with 2.5 μg / mL fusion protein containing one (MCB domain-1X) (SEQ ID NO: 4) or two (MCB domain-2X) MCB domains (SEQ ID NO: 2). The wells were then washed and binding was monitored by a secondary anti-human Fc-HRP conjugated detection antibody. The well signal was quantified at 450 nm using a multiwell plate reader (VarioSkan, ThermoFisher). As shown, the fusion protein containing two MCB domains (MCB domain-2X) domains bound CA125 in a more robust manner than the MCB domain-1X fusion protein. The experiment represents a minimum of triplicate wells. The accompanying stained gel ( Figure 2B ) indicates that similar amounts of pure input samples were used for each fusion protein. Human serum albumin (HSA) was used as an irrelevant protein to quantify nonspecific background binding.

[0027] Figure 3A-3B .Monitoring CD16a( Figure 3A ) or C1q( Figure 3B Binding of MCB Fc IgG1 fusion proteins of one (MCB-1X) or two (MCB-2X) MCB domains on ELISA plates to rituximab test antibody. ELISA plates were coated with 5 μg / mL rituximab and in the presence or absence of 30 KU / mL CA125, with or without 2.5 μg / mL MCB domain-1X or MCB domain-2X fusion proteins with biotinylated human CD16a Fc-γ receptor ( Figure 3A ) or C1q (Figure 3sB). The plates were washed and probed with streptavidin-HRP for secondary detection. The wells were quantified at 450nm using a multi-well Varioskan plate reader. As shown, CA125 significantly inhibited the binding of CD16a-biotin as well as C1q-biotin to the test antibodies. This effect was significantly reduced by the addition of MCB domain-2X fusion protein (SEQ ID NO:2) and to a lesser extent by MCB domain-1X fusion protein (SEQ ID NO:4). The experiments represent a minimum of triplicate wells.

[0028] Figure 4A-4B Monitoring the effect of MCB Fc fusion proteins containing one (MCB-1X) or two (MCB-2X) MCB domains on CA125 inhibition of CDC of rituximab (RTX) on Daudi cells ( Figure 4A ) or ADCC of NAV-007 on OVCAR3 cells ( Figure 4B) overcome. The MCB domain fusion protein can significantly reduce CA125's inhibition of C1q-mediated CDC and ADCC killing of the affected test antibodies. ( Figure 4A ) For CDC assays, 96 black well tissue culture plates were inoculated with 25,000 cells / well of CD20 positive Daudi cells (from Burkitt lymphoma patients) in 75 μL RPMI plus 1% heat inactivated fetal bovine serum (FBS), 1 μg / mL rituximab (RTX), and 1.3% rabbit complement (with or without 30 KU / mL CA125). In addition, PBS, 20 μg / mL of one MCB domain (MCB domain-1X) or two MCB domains (MCB domain-2X) domain Fc fusion protein were added to the wells. The plates were incubated at 37°C in 5% CO2 for 1.5 hours and then read by Cell-Titer using a multi-well Varioskan luminescent plate reader. (Promega) luminescence was used to quantify the viable cells. As shown in the figure, CA125 significantly inhibited the CDC killing of Daudi cells by rituximab. Similar effects were observed on Chinese hamster ovary (CHO) cells stably transduced to express human CD20 antigen. Interestingly and unexpectedly, the MCB domain-2X fusion protein significantly eliminated this inhibition in these two cell lines, but the MCB domain-1X fusion protein did not. The data are expressed as the percentage of CDC killing increased by dividing the effect of each RTX / MCB domain Fc fusion + / -CA125 treatment compared with RTX+ / -treatment. The experiment represents a minimum of triplicate wells. ( Figure 4B ) For ADCC assays, 5,000 OVCAR3 cells / well were seeded in at least duplicate wells of a 96-well tissue culture plate in 55 μL of RPMI complete medium (2 mM L-glutamine and 1% ultra-low Ig FBS serum) and incubated overnight at 37°C in 5% CO2. The next day, 300 ng / mL NAV-007 (a humanized IgG1 antibody against the cell surface OVCAR3 antigen) was added to the wells, along with PBS or 6 μg / mL MCB domain-1X or MCB domain-2X Fc fusion protein plus 75,000 Jurkat-CD16a-luc ADCC reporter cells (effector cell: target cell ratio of 15:1) and the plates were incubated at 37°C in 5% CO2 for 16 hours. ADCC activity was measured by Bio-Glo using a multi-well Varioskan luminescence plate reader according to the manufacturer's instructions (Promega). TM The percentage increase in ADCC activity of antibody plus MBC fusion protein relative to that of antibody alone was calculated as [(MCB domain + NAV-007 值 -NAV-007值 ) / NAV-007 值 ]x 100%. As shown in the figure, both MCB domain Fc fusion proteins were able to increase ADCC activity, and the CA125 inhibition of MCB domain-2X Fc fusion (70%, P = 0.018) was significantly more robust than that of MCB domain-1X Fc fusion (7%, P = 0.040), which is similar to the CDC data in panel A.

[0029] Figure 5 .Monitor the binding affinity of MCB Fc IgG1 fusion proteins containing one (MCB-1X) or two (MCB-2X) MCB domains to CA125. Multiple MCB domains increase the binding affinity of the fusion protein to CA125. MCB domain-1X (SEQ ID: 4) and MCB domain-2X (SEQ ID: 2) fusion proteins were captured on S series sensor chip protein A (GE Healthcare). C-terminal fragments with his tags from CA125 were serially diluted and injected into the surface of flow cells 1, 2, 3 and 4 to monitor binding, and then running buffer (10mM HEPES, 150mM NaCl, 3mM EDTA and 0.05% Tween-20, pH7.4) was injected to monitor dissociation. Flow cell 1 and buffer injection were used as double references for response unit subtraction. The data were processed using BiaCore T200 Evaluation Software Version 3.1 and the binding affinity was determined in molar units (M). As shown in the figure, KD = 6.52X10 compared to MCB domain-1X fusion protein. -11 M, MCB domain-2X protein showed higher binding affinity KD = 1.49X10 -11 M.

[0030] Figure 6.The effect of MCB-2X fusion protein on enhancing ADC killing. CA125 has a negative impact on the cytotoxicity of antibody drug conjugates (ADCs), while MCB domain fusion proteins can enhance the killing effect of ADCs on antigen-positive CA125-expressing tumor cells. Briefly, human ovarian cancer cell line OVCAR3 or its isogenic CA125 knockout line OVCAR-KO in 100 μL of RPMI complete growth medium (7.5% heat-inactivated FBS, 2mM L-glutamine, 1% penicillin) was used to inoculate 96-well plates at 5,000 cells / well. The next day, the wells were washed and 0, 1, 5, and 10 μg / mL of humanized anti-mesothelin IgG1 ADCs were added, with or without 20 μg / mL of MCB domain-2X fusion protein (SEQ ID NO: 2), and the cells were grown at 37°C in 5% CO2 for 120 hours, then washed and stained with crystal violet. The dried staining wells were dissolved using 1% SDS in phosphate buffered saline (PBS) and quantified by colorimetric densitometry at 570 nm on a VarioSkan multiwell plate reader. Panel A shows that ADC has the same significant enhancement in killing OVCAR-KO cells compared to parent OVCAR3. Panel B shows that, compared to ADC alone, when added to ADC, MCB domain-2X fusion protein can significantly enhance cell killing. No cytotoxicity was observed for MCB domain-2X fusion protein alone, indicating that the significantly enhanced killing power comes from the biological impact directly on ADC. The data are expressed as a percentage of killing, comparing the cell growth of cultures with different concentrations of ADC+ / -MCB domain-2X fusion protein and cultures without ADC.

[0031] Figure 7 Effect of MCB-2X Fc fusion protein on enhancing antibody internalization. Two MCB domain fusion proteins (MCB domain-2X) can enhance antibody uptake in CA125-expressing cells. Humanized anti-mesothelin antibody and negative control antibody (no antigen on target cells) were biotinylated and then incubated with Red avidin reagent (ThermoFisher), a fluorescent pH sensor dye, is combined, which significantly increases fluorescence as the pH of its surrounding environment becomes more acidic during internalization into the cell endosome. To test the ability of these antibodies to internalize alone or in the presence of MCB domain-2X fusion protein, OVCAR3 and OVCAR-KO cells were plated and probed for antibody uptake. In brief, 96 black well plates were inoculated with 100,000 cells / well harvested with PBS / EDTA. Next, the cells were pretreated with 20 μg / mL of MCB domain-2X fusion protein or PBS for 1 hour, and then 2 μg / mL of anti-mesothelin pHrodo antibody or non-specific pHrodo antibody control was added to the cells, incubated on ice for 1 hour, and then incubated at 37°C in 5% CO2 for up to 1 hour. The plate was read at 590nm on a multi-well Varioskan fluorometer. As shown in the figure, OVCAR-KO cells have more significant anti-mesothelin antibody uptake than OVCAR3 parental cells. In addition, OVCAR3 cells showed greater uptake when treated with the MCB domain-2X fusion protein compared to the control. Nonspecific antibodies showed no uptake in any of the cells. These values ​​represent the average of at least triplicate wells.

[0032] Figure 8 The relevant sequences used are shown. DETAILED DESCRIPTION

[0033] Proteins consisting of CA125 targeting proteins can effectively eliminate the immunosuppressive effects of CA125 on IgG1, IgG3 and IgM type antibodies. For example, mesothelin-human IgG1 Fc heavy chain fusion protein can target cells expressing CA125 as well as soluble CA125, and importantly, it can be used to block the humoral immunosuppressive activity of CA125. In addition, this fusion protein can be used to treat cancers expressing CA125 as a single agent or in combination with exogenously administered therapeutic immunoglobulin-based proteins, which can unlock the humoral immunosuppressive effects of autoantibodies produced by the patient's own immune system, which are directly or indirectly negatively affected by CA125.

[0034] We have developed therapeutic agents that can overcome the humoral immunosuppression of CA125 protein and improve the antibodies affected by CA125 to treat cancer and other CA125 immunosuppressive diseases. Although not wanting to be limited to any specific theory or mechanism of action, the applicant believes that CA125 protein binds to certain antibodies and SIGLEC receptors on NK cells, and inhibits the humoral immune response mediated by antibodies mediated by immune effector cells and / or complement cells. These destructions include inhibition of protein-antibody C1q-Ab (classical antibody-complement) complexes and / or Fc-γ activating receptors and antibody binding on immune effector cells (such as but not limited to NK cells), resulting in downstream inhibition of CDC and ADCC, respectively, and inhibition of immune effector cell activation when SIGLEC (sialic acid binding Ig-like lectin) receptors bind to Ab Fc-γ activating receptors, and / or inhibition of alternative complement pathway recognition protein binding. In addition, the applicant believes that using antibody drug conjugates, CA125 can inhibit the internalization of affected antibodies and block the ability to deliver cytotoxic agents to kill target cells internally.

[0035] The methods and kits described herein can be used to monitor and confirm the effectiveness of fusion proteins containing two or more MCB domains in overcoming humoral immune suppression. Fusion proteins that can eliminate the inhibitory effect of CA125 on the humoral immune response (including ADCC and / or CDC) of the test antibody are suitable for preclinical and human testing.

[0036] Some methods, compositions and kits can be divided into two categories. In one category, different fusion partners (called "ankyrin") and spacers are used to test fusion proteins containing two or more MCB domains to determine the maximum effectiveness of overcoming the inhibition of ADCC and / or CDC by CA125, as determined using a molecular assay, which monitors the binding of Fc-γ activating receptors CD16a or CD32a or C1q complement proteins to the test antibody in the presence of CA125. In another category, the fusion protein comprises two or more MCB domains fused to ankyrin human IgG1 Fc heavy chain (SEQ ID: 2), and is tested in combination with a test antibody to determine the maximum effectiveness of overcoming the inhibition of ADCC and / or CDC by CA125, as determined using a cell viability assay. The test antibody can be added to the antigen-positive target cells expressing CA125, or CA125 can be added to the non-expressing cells with fusion protein exogenously, and its ADCC activity can be measured by adding immune effector cells (NK, dendritic / bone marrow / monocytes, peripheral blood mononuclear cells or ADCC reporter cell lines); or human or rabbit complement is added to monitor CDC activity. In either assay, the cell viability between cells treated with or without fusion protein is compared to determine whether fusion significantly blocks the CA125 humoral immune response of the test antibody. CA125 can be produced from target cells or exogenously added to cell culture. Cell viability is determined using a variety of methods used by those skilled in the art.

[0037] In other embodiments, different anchor proteins and different spacers are used to test fusion proteins comprising two or more MCB domains to determine the maximum effectiveness of overcoming the inhibition of CA125 to test antibody internalization. In the presence of positive antigen-expressing cells with CA125 and fusion proteins, internalization can be determined by using a labeled test antibody. CA125 can be produced by target cells or added to cell culture exogenously. Internalization can be determined by the uptake of labeled test antibodies by cells, and monitored by using a variety of methods used by those skilled in the art. Alternatively, ADC can be used to monitor internalization, in which the toxic agent becomes cytotoxic after the cell enzyme releases the antibody. ADC can be applied to antigen-positive cells expressing CA125, which are treated with or without fusion proteins, and cell viability can be monitored by using a variety of methods used by those skilled in the art.

[0038] Test antibodies include, but are not limited to, anti-cancer antibodies that can be derived from patient antibodies, which can be collected from the patient to be treated, collected from a different patient, or prepared in the laboratory by other recombinant DNA or cell methods. Patient antibodies can be modified in various ways before use. Certain commercial or experimental anti-cancer antibodies that can be tested using the methods of the invention include, but are not limited to, rituximab, trastuzumab, trastuzumab emtansine, cetuximab, YP218, ocrelizumab, daratumumab, elotuzumab, alemtuzumab, necitumumab, pertuzumab, obinutuzumab, nivolumab, ipilimumab, pembrolizumab, ofatumumab, panitumumab, tiuxetan, saccharotuzumab govitecan, brentuximab vedotin, and tositumomab. Those antibodies that have improved humoral immune function (ADCC or CDC) and / or improved internalization are candidates for combined therapy using the best fusion protein and the affected test antibody.

[0039] For therapeutic applications, the MCB domain fusion proteins can be administered as monotherapy with standard of care therapy and / or in combination with an affected test antibody.

[0040] Compositions can be formed in the process of carrying out these methods. For example, they can be preformed and packaged and provided to an entity with an ankyrin fusion library to be screened or different linkers can be used to connect MCB domains of different lengths to each other or to an entity of ankyrin. Similarly, the components of the assays and methods described herein can be packaged together in a container and sold as a kit. The components of the kit do not have to be mixed together, but can be mixed together. For example, they can be provided in separate containers or separate containers. Any selection of the antibodies and MCB domain fusion proteins described herein can be formed into a composition or a kit.

[0041] While some antibodies are known to be susceptible to CA125 immunosuppression, the compositions described herein can be used for any antibody whose dynamic structural changes lead to inhibition of humoral immunity and / or pharmacological responses, such as in the case of ADC internalization or humoral immune responses.

[0042] The "dynamic structure" of an antibody or protein is defined as the three-dimensional structure of the antibody at a given time point, wherein the time point is consistent with the combination of the antibody with another protein or agent, and the antibody structure before this time point responds to the combination of the antibody with another protein or agent and has become a different structure after this time point. Monitoring this change in the presence of MCB domain fusion protein is a method taught in this application. In the case of hapten binding to the CDR domain of an antibody, it has been reported that the protein binds to the antibody and affects its dynamic structure, which in turn changes its Fc domain allosterically, thereby reducing its binding to Fc binding proteins including Fc receptors (Janda A, et al. Front Microbiol 7: 22, 2016). Previous studies have also shown that when an antibody binds to its antigen, the dynamic structure of the (FAB')2 domain is affected (Werner TC, et al. Proc Natl Acad Sci 69: 795-799, 1972). Recently, Kline et al. reported that although several humanized monoclonal IgG1-type antibodies have similar amino acid structures, there are significant differences in the ability of CA125 to bind them, suggesting that primary or secondary structure may determine CA125 antibody binding (Kline JB et al. OncoTarget 8: 52045-52060, 2017). Given the increasing evidence that tumors use various pathways to avoid host immune defenses, and the fact that antibody-based approaches continue to be used to combat various cancer types as well as inflammatory and infectious diseases, it is very important to identify agents and define methods that can treat and overcome humoral immune suppression of affected antibodies, such as the case of MCB domain fusion proteins. These agents and methods, in turn, can select lead antibodies that can overcome CA125 immunosuppression and can be used for patient screening. For example, if the test antibody is found to be affected by CA125, patients can be pre-screened to determine whether their tumors or diseases express CA125. For those patients who do so, an optimized MCB domain fusion protein agent can be used that can overcome the inhibitory effects of CA125 on humoral responses or ADC uptake. In this case, the agent can be a MCB domain fusion protein consisting of two or more MCB domains, which are connected by a spacer and fused to an anchor protein. Alternatively, a peptide having at least two MCB domains can be used, which are combined with a polymer of at least 60 kDa to form a conjugate of at least 60 kDa, or combined with a liposome. In the case of a fusion protein, the anchor protein can be the Fc domain of a human IgG1 heavy chain containing its disulfide bridge. It is desirable that the molecular weight of the anchor protein or chemical matrix is ​​sufficient to avoid renal excretion and a short serum half-life.For proteins, the ankyrin or fusion protein thus formed may have a molecular weight of at least 60 kDa if it is a monomer, or at least 30 kDa if the protein forms a multimer (dimer or higher order structure).

[0043] Suitable anchoring polymers include, but are not limited to, those that are safe and preferably biodegradable. These can be natural products or synthetic polymers. The most popular polymer for this purpose is currently polyethylene glycol, but other polymers can also be used, including but not limited to dextran, hyaluronic acid, polysialic acid, hydroxyethyl starch and poly (2-ethyl 2-oxazoline). The polymer can be connected to the MCB domain by chemical conjugation, genetic fusion or enzymatic action. If necessary, a cleavable linker can be used.

[0044] Any liposome formulation for delivering proteins and peptides can be used to deliver two or more MCB domains to patients. Traditional liposomes are composed of a lipid bilayer composed of cationic, anionic or neutral (phosphoric acid) lipids and cholesterol, which surrounds a water volume. Suitable compositions of liposomes include but are not limited to guanidine-cholesterol cationic lipids bis(guanidine)-tren-cholesterol (BGTC) combined with lipid dioleoylphosphatidylethanolamine (DOPE). Another example of a suitable liposome formulation is the aminoglycoside lipid dioleyl succinyl paromomycin (DOSP) combined with an imidazole-based auxiliary lipid MM27. Liposomes can be spatially stable, for example, using polyethylene glycol coated liposomes. If desired, liposomes can be ligand-targeted. Suitable ligands include antibodies, peptides, carbohydrates and proteins.

[0045] We provide compositions, kits and methods for screening antibody dynamic structures in the presence of CA125, which can affect antibody dynamic structures and inhibit its downstream immune effector function and / or cellular internalization after binding to its cell surface target antigen. The method includes the steps of composing and using an Fc fusion anchor protein comprising two or more MCB domains, which can bind to CA125, which binds to tumor cell membranes and / or acts as a soluble factor and blocks its inhibitory effect on the affected test antibody. Fusion protein (or medicament) can include two or more MCB domains, which are fused to the N- or C- terminus of the immunoglobulin Fc heavy chain domain, or fused to a full-length immunoglobulin, wherein the MCB domain is fused to the N- terminus of a light chain or a heavy chain. The medicament can also include fusing two or more MCB domains with other anchor proteins, such as, but not limited to, human albumin, TNF receptor, TGF receptor, cytokine receptor and / or nanobeads. The fusion protein may also comprise two or more MCB domains linked to a tag-modified anchor protein for detecting binding to membrane-bound CA125 for diagnosis of CA125-positive tumors and for delivery of cytotoxic agents such as radionuclides and small molecule cytotoxic agents that localize to the cell outer membrane by interacting with CA125 and delivering a cytotoxic payload. Figure 1 Illustrative examples are provided, but not limited to the types of fusion proteins that can be produced and their compositions, which contain two or more MCB domains connected to an anchor protein such as an immunoglobulin Fc heavy chain domain. In some embodiments, the fusion protein contains two MCB domains fused to the N-terminus of a human IgG1 Fc heavy chain domain. In other embodiments, the agent contains three MCB domains fused to the N-terminus of a human IgG1 Fc heavy chain domain. In yet other embodiments, the fusion protein contains four or more MCB domains fused to the N-terminus of a human IgG1 Fc domain. In yet other embodiments, two or more MCB domains are fused to an anchor protein other than a human IgG1 Fc heavy chain domain, whereby the fusion can be located at the N- or C-terminal domain or at both domains.

[0046] In some embodiments, the fusion protein or agent comprises two or more MCB domains fused to another protein (called ankyrin), the molecular size of the other protein as a monomer is at least 60 kDa, and if a higher order dimer or multimer is formed, its size is 30 kDa, to provide sufficient molecular weight to avoid urinary excretion and short pharmacokinetic half-life (Farguhar M. Kideny Int 8: 197-211, 1975) of the treated subject. The affected test antibody of the test fusion protein or agent overcomes the ability of CA125 humoral immunosuppression to ADCC or CDC. In some embodiments, if it is a monomer, the fusion protein is at least 60 kDa, or if it is a dimer or multimer, the fusion protein is at least 30 kDa.

[0047] In other embodiments, two or more MCB domains are linked to the ankyrin in series or in a random manner at the N- or C-terminus. For example, one or more MCB domains can be linked to the N- and C-termini of the ankyrin using genetic fusion or chemical bonds.

[0048] Another embodiment has MCB domains connected in series using an amino acid linker unit consisting of the amino acids GGGGS. The linker consists of one or more linker units. As an example, but not wishing to be limiting, the MCB domains can be connected to one (GGGGS), two (GGGGSGGGGS), three (GGGGSGGGGSGGGGS) or more (GGGS) x , wherein linker optimization is determined by optimal binding to CA125 of the fusion protein or the effect on the humoral immune response of the affected test antibody in the presence of CA125, as measured by ADCC, CDC or antibody internalization using any method used by one of skill in the art, as described herein.

[0049] In yet another embodiment, the Linker unit consists of any combination of known natural or modified amino acids and any length that can genetically link two or more MCB domains to an anchor protein that can be empirically tested to reduce antibody-mediated suppression of humoral immunity and / or affected internalization of the test antibody.

[0050] In one method of measuring the ability of MCB domain fusion proteins to effectively overcome CA125 humoral immunosuppression and antibody dynamics; the ability of the reagent to directly bind and release the affected antibody to bind CD16a or Clq protein is tested by ELISA or other methods known to those skilled in the art.

[0051] In some embodiments, functional methods are used to measure the effect of MCB domain fusion proteins on overcoming the humoral immunosuppression of CA125 on the affected test antibodies using ADCC, CDC or internalization assays. The term "effect" generally refers to a 10% or greater change in ADCC, CDC or ADC target cell killing compared to an antibody with CA125 when the agent is incubated with a separate test antibody. Depending on the antibody and agent used, it may also refer to a change of at least 5%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70% or 75%.

[0052] Another embodiment includes a method for screening antibody drug conjugates (ADC) that may be affected by CA125, which can change their pharmacokinetic (PK), pharmacodynamics (PD) or pharmacological (PL) activity, including cell internalization. In some embodiments, ADC is added to cells and the effect of target cell killing is tested in the presence or absence of MCB domain fusion protein agents. The affected ADCs that enhance lethality in the presence of agents are now suitable for therapeutic testing. Similarly, depending on the antibody and agent used, the term effect can refer to at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70% or 75% change.

[0053] Various terms and expressions ("terms") related to various aspects of the attached description are used throughout the specification and claims of this document. Unless otherwise specifically stated, these terms are to be given their ordinary meanings in the art. Other specifically defined terms should be interpreted in a manner consistent with the definitions provided.

[0054] As used in this specification and the appended claims, the singular forms "a", "an", and "the" also include plural references unless the context clearly dictates otherwise. For example, reference to "a cell" may include a combination of two or more cells, etc. Reference to a "probe" may include a test antibody, an MCB domain fusion protein, or an independent probe to monitor a humoral immune response by any analytical method known to those skilled in the art.

[0055] The term "about" used when referring to quantitative values ​​such as amounts, time periods, and / or the like is intended to cover variations of up to ±9% from the specified value, as such variations are suitable for performing the disclosed methods. Unless otherwise indicated, all values ​​used in the specification and claims representing the amount of reagents, such as molecular weight, molar concentration, reaction conditions, percentages, etc., are to be understood as being quantified in all cases by the term "about". Therefore, unless otherwise indicated, the numerical values ​​listed in the following specification and the listed claims are approximate values, which may vary depending on the desired properties of the composition and / or the methods sought to be obtained by the present invention. At a minimum, rather than attempting to limit the scope of the present application, each numerical value should at least be rounded to the nearest integer reported and by ordinary rounding methods known to those skilled in the art.

[0056] The term "antibody" as used is broad and includes immunoglobulins (also known as "Ig") or antibody molecules, including polyclonal antibodies (also known as pAbs), monoclonal antibodies (also known as mAbs), including murine, human, humanized and chimeric mAbs, bispecific antibodies (also known as BSPs), antibody drug conjugates (also known as ADCs), antibody fusion immunotoxins and antibody fragments. In general, antibodies are proteins or polypeptide chains that bind to a specific antigen. The antigen is the structure specifically recognized by a given antibody. Typical antibodies contain heterotetrameric glycosylated proteins, consisting of two light chains and two heavy chains arranged by a complex of disulfide bonds and hydrogen bonds. The term "its disulfide bridge" refers to the disulfide bridge contained in the hinge region of the heavy chain, which is well known to those skilled in the art. Each heavy chain has a variable domain (variable region) (VH) followed by multiple constant domains (called Fc domains). Each light chain has a variable domain (VL) and a constant domain; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain VL is aligned with the variable domain of the heavy chain. The light chains of any class of antibodies are assigned to one of two different types, kappa (κ) and lambda (λ), based on the amino acid sequence within their constant domains.

[0057] Immunoglobulins are divided into classes or isotypes, depending on the type of Fc domain, namely IgA, IgD, IgE, IgG and IgM, depending on the sequence contained in the constant domain of their heavy chains. IgA and IgG isotypes are further divided into subclasses, such as isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4.

[0058] The immunoglobulin VL or VH region consists of a "framework" region interrupted by three "antigen binding sites" also called complementarity determining regions (CDRs), based on reported sequence variability (Wu TT, Kabat EA. J Exp Med 132: 211-250, 1970). Typically, one antigen binding site consists of six CDRs, three of which are located in VH (CDRH1, CDRH2, CDRH3) and three in VL (CDRL1, CDRL2, CDRL3) (Kabat EA, et al. 5 th Ed. PHS, National Institutes of Health, Bethesda, Md., 1991).

[0059] "Specific binding" or "specifically binds" means that the antibody or antigen-binding fragment binds to the antigen (including sequences contained in the antibody itself) with greater affinity than to other antigens. -8 The equilibrium dissociation constant K is M or smaller D Binds to target antigen.

[0060] An "antibody derivative" refers to an antibody as defined above that has been modified by the covalent attachment of another molecule, for example, by peptide chemistry (i.e., amidation, etc.), genetic fusion, and / or by a post-translational moiety that is not normally associated with an antibody (i.e., sugar groups, acetyl groups, and / or phosphoryl groups), etc.

[0061] The term "antibody dynamic structure" refers to any structural changes that may affect the humoral function or internalization of the antibody.

[0062] The term "monoclonal antibody (mAb)" refers to an antibody derived from a single cell clone, including any eukaryotic or prokaryotic cell clone or phage clone, rather than the method of production thereof. Therefore, the term "monoclonal antibody" is not limited to antibodies produced by hybridoma technology, but may also include recombinant methods.

[0063] "Fab domain" refers to any antibody sequence N-terminal to the antibody hinge disulfide bond region known to those of skill in the art.

[0064] "Fc domain" refers to any antibody sequence that is C-terminal to the antibody hinge disulfide region and includes the hinge disulfide region known to those skilled in the art.

[0065] "Ankyrin" refers to any protein to which an MCB domain can be fused by genetic or chemical linkage. If the ankyrin and / or genetically linked fusion protein or conjugate forms only monomers, its molecular weight is equal to or greater than 60 kDa, and if it forms multimers (dimers, trimers, tetramers, or higher order structures), its molecular weight is equal to or greater than 30 kDa. In some cases, non-peptide polymers can be used instead of ankyrin. In this case, a conjugate is formed.

[0066] "MCB domain" refers to the minimal binding domain from human mesothelin protein to which CA125 / MUC16 binds (SEQ ID NO: 1), but may include larger fragments of mesothelin protein, including the entire protein itself (GenBank: AAH03512.1) or altered amino acid sequences that may improve affinity binding. The two or more copies of the MCB domain in a protein may be adjacent, such as tandem repeats, or may be at different locations within the polypeptide, for example, one or more at the amino terminus and one or more at the carboxyl terminus. For example, a polypeptide comprising more than one MCB domain may be a monomer. The number of MCB domains does not determine the higher order structure of the entire protein, i.e., whether a dimer, trimer, tetramer, etc. is formed.

[0067] An "antigen" is an entity to which an antibody or antibody fragment specifically binds. This includes binding to an antibody or protein of interest.

[0068] The term "test antibody" refers to an antibody for which humoral immunosuppression of CA125 is tested, and the MCB domain fusion protein can be tested to overcome CA125 immunosuppression by molecular or biological functional assays.

[0069] The term "CA125" refers to a gene product produced by the MUC16 gene (HGNC: 15582; OMIM: 606154), which exists in soluble and membrane-bound forms. It is reported that it binds to antibodies and affects the humoral immune function of the bound antibodies (Kline JB, et al. Oncotarget 8: 52045-52060, 2017).

[0070] The terms "cancer", "malignant" and "tumor" are well known in the art and refer to the presence of cells with unregulated cell growth and morphological characteristics that are different from normal cell types of similar origin, also known as dysregulated cells. Malignant refers to those cancer cells that are capable of causing morbidity and / or mortality. As used, "cancer and tumor" include both precancerous and malignant types.

[0071] As used, the term "soluble" refers to a protein or non-protein agent that is not attached to the cell membrane of a cell. For example, a soluble agent can be shed, secreted or exported from a normal or cancer cell into a biological fluid, including serum, whole blood, plasma, urine or microfluidics of cells, including tumors.

[0072] The term "labeled" with respect to MCB domain fusion proteins (also referred to as "probes") is intended to encompass direct labeling of probes by coupling (i.e., physically connecting) a detectable substance to a probe (e.g., such as, but not limited to, fluorescence, enzymes, radionuclides, etc.), as well as indirect labeling of probes by reacting with another reagent of direct labeling. An example of indirect labeling includes detecting a primary probe by a secondary fluorescent labeling probe, which may include an antibody or aptamer specific to the probe. In one embodiment, a primary or secondary probe is labeled by a radionuclide, a chromophore, a fluorophore, or an enzyme. In another embodiment, the probe or secondary probe is an antibody derivative, an antibody fragment, a protein scaffold capable of targeting specific binding, or an aptamer labeled with a protein ligand (e.g., a ligand of biotin, avidin, and streptavidin). In yet another embodiment, the probe is used for in vitro or in situ detection of CA125-positive cells.

[0073] The term "detection agent" or "detectable agent" refers to any agent that can be linked to the MCB domain fusion protein, including but not limited to protein binders and / or aptamers, and detected by equipment commonly used in the art. These include but are not limited to fluorescence, enzymes and enzyme substrates, radionuclides, heavy metals and colorimetric dyes, and substrates that can be detected by methods such as but not limited to densitometry, spectrophotometry, luminescence, microscopy, radiography, and scintillation. Additional agents may be required to produce a detectable signal.

[0074] As used, the "level" of a specific protein or non-protein reagent including MCB domain fusion protein and CA125 refers to one or more levels of a reagent determined using any method known in the art for measuring protein and / or non-protein reagent levels in vitro or in vivo. Such methods include gel electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), superdiffusion chromatography, fluid or gel precipitation reaction, absorption spectrum, colorimetric determination, spectrophotometry, flow cytometry, immunodiffusion (single or double), solution phase determination, immunoelectrophoresis, Western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay, fluorescence resonance energy transfer (FRET), Foster resonance energy transfer, electrochemiluminescence immunoassay, etc. In one embodiment, the level of CA125 is determined using probe-based technology, as described in more detail. In another embodiment, the level of MCB domain fusion protein uses probe-based technology.

[0075] The term "humoral immunity-suppression or humoral immunosuppression" refers to any antibody, antibody fragment, bispecific antibody (BSP) or antibody drug conjugate (ADC) that directly binds to CA125 and changes its dynamic structure. It is reported that CA125 is produced by malignant cells such as ovarian cancer and mesothelioma (Nicolaides NC, et al. Cancer Biol Ther 19: 622-630, 2018) and induced by lymphoma from normal surrounding epithelial cells (Sanusi et al. Perit Dial Int. 21: 495–500, 2001), which can bind to certain antibodies and change their dynamic structure, thereby affecting their biological activity, including ADCC, CDC, opsinization, internalization and / or PK, PD and PL spectra.

[0076] The term "antibody drug conjugate (ADC)" refers to any antibody coupled or fused to a chemical, polypeptide, nucleic acid, or radionuclide that is toxic to cells.

[0077] The term "bispecific antibody (BSP)" refers to any antibody that can bind to two or more different antigens. A BSP may comprise at least, but not limited to, two full-length antibodies, one full-length antibody and one single-chain antibody, or two single-chain antibodies, each of which binds to a different antigen or a different epitope on the same antigen.

[0078] The term "antibody-dependent cellular cytotoxicity (ADCC)" refers to an in vitro or in vivo process in which antibodies can bind to antigens on the surface of cells and then bind to immune effector cells through sequences within the antibody Fc domain, which in turn causes them to release toxins that can kill the bound cells.

[0079] The term "complement-dependent cytotoxicity (CDC)" refers to an in vitro or in vivo process in which antibodies can bind to antigens on the surface of eukaryotic or prokaryotic cells and then bind to the C1q protein through sequences within the antibody Fc domain, which in turn leads to the initiation of the classical complement cascade that can kill the bound cell.

[0080] The term "opsonization" refers to a process whereby antibodies can bind to antigens on the surface of cells and then bind to immune cells through sequences within their Fc domains, which in turn causes the immune cells to engulf, consume, and ultimately kill the cell to which the antibody is bound.

[0081] The term "internalization" refers to a process whereby an antibody, antibody fragment or ADC can bind to an antigen on the surface of a cell and then be internalized by mechanisms known to those skilled in the art.

[0082] The term "pharmacokinetics (PK)" refers to the time it takes an antibody to maintain its steady state concentration when administered to a subject.

[0083] The term "pharmacodynamics (PD)" refers to the study of the biochemical and physiological effects of antibody-based drugs and their mechanisms of action, including the correlation of their actions and effects with their biochemical structure when administered to a subject.

[0084] The term "pharmacology (PL)" refers to the known effects of an antibody on the control or killing of disease cells in vitro or in vivo.

[0085] The term "sample" refers to a general term for similar fluids, cells or tissues isolated from a subject, as well as fluids, cells or tissues present in a subject. Fluids may include biological fluids, which include liquid solutions in contact with a subject or biological source, including cell and organoid culture media, urine, saliva, lavage fluids, etc.

[0086] As used, the term "control sample" refers to any clinically or non-clinically relevant control sample, including, for example, samples from healthy subjects not suffering from a particular cancer type or cells other than their parental cells.

[0087] The term "control level" refers to an accepted or predetermined level of a protein or non-protein agent for comparison with the level of the same agent in a sample derived from a subject or used in an in vitro assay.

[0088] As used, the "difference" between the signal of the test antibody in the control and the signal bound by CA125 in the presence or absence of the MCB domain fusion protein is generally any difference that can be statistically determined using statistical methods commonly used by those skilled in the art, and compared to the control, there is at least a 10% or greater difference. Depending on the antibody and probe used, it can also refer to a change of at least 5%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70% or 75%.

[0089] The term "inhibit" or "inhibition thereof" means to reduce by a statistically measurable amount, or to prevent completely.

[0090] In the context of an antibody, an antibody-containing portion (i.e., BSP, ADC, etc.) or an MCB domain fusion protein used according to the method, the term "functional" means that the antibody and / or fusion protein is able to bind to the antigen or CA125, respectively, and / or is able to bind to and kill target cells in vitro or in vivo.

[0091] The term "target cell" refers to a eukaryotic or prokaryotic cell or cell population that expresses a specific antibody or antigen comprising an antibody portion.

[0092] The term "pharmaceutically acceptable" refers to a substance that is pharmacologically and toxicologically acceptable for administration to a patient and is manufactured using methods known to those skilled in the art. These include agents for use in animals and humans that are approved by regulatory agencies of the federal or state governments or listed in the U.S. Pharmacopeia or other generally recognized pharmacopoeias. The term "pharmaceutically compatible ingredients" refers to a pharmaceutically acceptable diluent, adjuvant, excipient, or matrix carrier that is administered with an anticancer agent. A "pharmaceutically acceptable carrier" refers to a matrix that does not interfere with the effectiveness of the biological activity of the active ingredient and is nontoxic to the host.

[0093] The terms "effective amount" and "therapeutically effective" are used interchangeably and are used in the context of administering an agent in an amount sufficient to produce an enhanced clinical outcome in a patient. An effective amount of the agent is administered according to the methods described in the "effective regimen". The term "effective regimen" refers to a combination of an amount of an agent and a dosing frequency sufficient to achieve an enhanced clinical outcome for a patient with a particular cancer. When an agent that is able to overcome morbidity better than the parent compound or an agent that is able to enhance the clinical outcome of an effective regimen is administered to a patient, the enhanced efficacy is an improved clinical outcome. As in this context, an effective amount refers to the amount of the MCB domain fusion protein required to demonstrate efficacy or a difference when compared to no MCB domain fusion protein.

[0094] The terms "patient" and "subject" are used interchangeably and refer to humans and other non-human animals, including veterinary subjects, who are treated with a therapeutic agent. The term "non-human animal" includes all vertebrates. In one embodiment, the subject is a human.

[0095] A "therapeutic agent" is typically substantially free of undesirable contaminants. This means that the agent is typically at least about 50% w / w (weight / weight) pure and is substantially free of interfering proteins and contaminants.

[0096] The term "immune effector cell" refers to any cell that can confer antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (opsonization) upon binding to an antibody-bound target cell, including but not limited to NK, bone marrow, monocytes, dendritic cells. The cells can be purified or present in the form of a mixture of peripheral blood mononuclear cells (PBMC).

[0097] The term "dysregulated cell" refers to any cell that is considered abnormal to the parent cell. These include transformed cells, malignant cells, virally infected cells, cells that grow autonomously through autoregulation, or prokaryotic pathogens.

[0098] The term "humoral response" refers to ADCC, CDC, or internalization of the antibody into target cells by the test antibody.

[0099] The term "agent" or "MCB domain fusion agent" or "MCB domain fusion protein" refers to any fusion protein comprising two or more MCB domains genetically or chemically linked to ankyrin. If the ankyrin is a monomer, the molecular weight of the fusion protein, conjugate and / or ankyrin is 60 kDa or greater, or if the ankyrin forms a multimer (dimer or structure with a higher order of magnitude), the molecular weight of the fusion protein, conjugate and / or ankyrin is 30 kDa or greater.

[0100] The term "screening" can refer to testing the MCB domain fusion protein that can bind CA125 and looking for the enhanced biological response of monitoring ADCC, CDC or ADC lethality in the presence of a test antibody or a part containing the antibody (i.e., BSP, ADC, single-chain antibody, antibody fragment, etc.). The term can be used in other environments, in which a large number of test elements are being analyzed to determine which elements in the test elements have specific properties. Similarly, it can be used to refer to analyzing patient samples with specific characteristics. Fusion proteins, proteins or conjugates can be used for such screening.

[0101] The term "significantly" refers to a statistical result having a P value less than 0.05 as determined by various procedures including Student's T-test.

[0102] Compositions, kits and methods of therapeutic fusion proteins for overcoming CA125-mediated humoral immune suppression for treatment

[0103] Provided herein are compositions (agents), kits, and methods for identifying agents that can effectively inhibit the inhibition of humoral immune responses of affected test antibodies by CA125. In some embodiments of the methods described herein for identifying the best MCB domain fusion proteins, the method involves producing MCB domain fusion proteins containing two or more MCB domains, which are connected by amino acid spacers and genetically fused to an anchor protein, and testing the ability of the affected test antibodies or ADCs to have significantly improved biological activity when used to mediate ADCC, CDC, or toxin-induced killing of target cells. In some embodiments, the MCB domain fusion protein is composed of two MCB domains fused to a human IgG1Fc heavy chain domain, wherein the heavy chain retains the disulfide bridge domain in the hinge region. In other embodiments, the MCB domain fusion protein consists of two or more MCB domains connected by an amino acid spacer and fused to an ankyrin derived from a protein other than immunoglobulin IgG1, wherein the molecular weight of the ankyrin is 60 kDa or greater if it is a monomer, or 30 kDA or greater if it forms higher order dimers or multimers to avoid renal clearance and extend PK half-life. In other embodiments, the MCB domain fusion consists of at least two MCB domains connected by an amino acid spacer and is pegylated, conjugated to serum albumin, bound by an antibody and / or modified by other modifications to produce a fusion molecule of 60 kDa or greater molecular weight. In other embodiments, the MCB domain fusion protein has three or more MCB domains connected by an amino acid spacer and fused to ankyrin. The fusion can be by genetic fusion to the N-terminus or C-terminus of the ankyrin, and the configuration of the MCB domains can be in tandem order or separated by connection at the N-terminus and C-terminus of the ankyrin, such as in Figure 1 D Example. The connection between the tandem MCB domains is through a genetic linker encoding the amino acid linker unit GGGGS. The connection can be through one or more units. In the presence of the affected test antibody, CA125 and target cells, a functional ADCC, CDC or ADC killing assay can be used to determine the optimal spacer unit. The example is schematically shown in Figure 1 The kit consists of an MCB domain fusion protein, which can significantly overcome the humoral immune suppression of CA125 on the affected test antibody by using ADCC, CDC or ADC killing assays used by those skilled in the art.

[0104] In yet another embodiment, the fusion protein has a molecular weight greater than kDa=6.5 x 10 -11M (65pM). For example, the binding affinity can be greater than 50pM, 25pM, or 10pM. The lower the dissociation constant, the higher the affinity.

[0105] In the method for identifying active MCB domain fusion proteins, the affected test antibody is added to a culture of target cells, wherein the target cells express CA125 naturally or recombinantly. Using standard ADCC, CDC or ADC killing assays, the humoral response of the culture is monitored, and the culture compares the humoral response of those with MCB domain fusion proteins with those without such proteins. A change of at least 10% is generally considered to have a significant effect on ADCC, CDC and / or ADC function. Depending on the antibody and assay used, a significant effect can also be defined as a change of at least 5%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70% or 75%.

[0106] In the method for identifying active MCB domain fusion proteins, the affected test antibody is added to a culture of target cells, wherein the target cells naturally express CA125. Using standard ADCC, CDC or ADC killing assays, the humoral response of the culture is monitored, and the culture compares the humoral response of those with MCB domain fusion proteins with those without such proteins. A change of at least 10% is generally considered to have a significant effect on ADCC, CDC and / or ADC function. Depending on the antibody and assay used, a significant effect can also be defined as a change of at least 5%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70% or 75%.

[0107] Another method for identifying active MCB domain fusion proteins measures the internalization of the affected test antibody in target cells expressing CA125. The affected antibody can be labeled and added to target cells with or without the MCB domain fusion protein to compare internalization. A change of at least 10% is generally considered a significant effect. Depending on the antibody and assay used, a significant effect can also be defined as a change of at least 5%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70% or 75%.

[0108] Also provided herein are methods for treating a subject with cancer using an MCB domain fusion protein. For example, a patient may have a cancer that expresses mesothelin, such as mesothelioma, colorectal cancer, lung cancer, ovarian cancer, pancreatic cancer, bile duct cancer, or endometrial cancer. It has been reported that several anti-mesothelin antibodies bind to CA125, making the use of an effective MCB domain fusion protein an ideal entity. Another such antibody is anti-CD20 rituximab, which clinical studies have found to significantly inhibit the therapeutic effect in patients with high serum CA125 levels. Rituximab has been found to bind to CA125. The use of an effective MCB domain fusion protein for this antibody is also highly desirable.

[0109] In some embodiments of the method for treating a subject with an MCB domain fusion protein, the patient with a cancer expressing CA125 can be treated with the MCB domain fusion protein alone or in combination with a standard of care therapy. In some embodiments of the method for treating a subject suffering from a cancer expressing CA125 as described herein, the MCB domain fusion protein is administered to the subject, wherein the subject has a baseline CA125 level higher than the normal range. In some embodiments of the method for treating a subject suffering from a cancer expressing CA125 as described herein, the method includes administering the MCB domain fusion protein alone. In yet another embodiment, the MCB domain fusion protein is administered in combination with chemotherapy. Chemotherapy can be cisplatin, carboplatin and / or pemetrexed, or any other chemotherapeutic agent that is considered to be a standard of care when treating a subject. In the methods of treatment described herein, the CA125 expression level can be determined by any means known in the art and defined by those skilled in the art as being within or above the normal range.

[0110] In some embodiments of the treatment methods described herein, the MCB domain fusion protein consists of two MCB domains connected in series by an amino acid spacer and fused to the N-terminus of human IgG1 Fc heavy chain anchor protein (SEQ ID NO: 2). The agent is administered to a patient with a cancer expressing CA125. Exemplary cancers known to produce CA125 include, but are not limited to, mesothelioma, lymphoma, lung cancer, colorectal cancer, ovarian cancer, endometrial cancer, bile duct cancer, and pancreatic cancer.

[0111] The present method can be combined with other treatments, such as surgery (e.g., tumor reduction surgery), radiation, targeted therapy, chemotherapy, immunotherapy, the use of growth factor inhibitors or anti-angiogenic factors. The MCB domain fusion protein can be administered simultaneously to patients receiving surgery, chemotherapy or radiotherapy. Alternatively, the patient may receive surgery, chemotherapy or radiotherapy at least one hour to at most several months before or after the administration of the MCB domain fusion protein, for example, at least one hour, five hours, 12 hours, one day, one week, one month or three months before or after standard care treatment. Some embodiments of the treatment methods provided herein include administering to the subject a therapeutically effective amount of platinum-based chemotherapy and / or folic acid anti-metabolites plus antibodies to tumor-specific antigens in addition to the MCB domain fusion protein.

[0112] In some embodiments of the treatment methods described herein, the subject may have received first-line surgical resection of the tumor, first-line platinum-based therapy, first-line folate antimetabolite-based therapy, and / or first-line platinum and folate antimetabolite-based therapy for the treatment of the cancer and is then administered an antibody specific for an antigen expressed by the cancer and the MCB domain fusion protein.

[0113] Therapeutic agents (including antibody therapeutics, folate antimetabolites, and / or platinum-based chemotherapy and MCB domain fusion proteins) can be administered in accordance with the treatment methods described herein by any means known in the art.

[0114] In yet another embodiment, a therapeutic antibody comprising CDR sequences that can direct the antibody to bind to the CD20 antigen: SEQ ID NO: 5 (GYTFTSYN) as CDRH1, SEQ ID NO: 6 (IYPGNGDT) as CDRH2, SEQ ID NO: 7 (ARSTYYGGDWYFNV) as CDRH3, SEQ ID NO: 8 (SSSVSY) as CDRL1, SEQ ID NO: 9 (ATS) as CDRL2, and SEQ ID NO: 10 (QQWTSNPPT) as CDRL3 may be used, according to (International ImmunoGeneTics ) number. The antibody can be administered to disease indications expressing CD20 and CA125 is above the normal range when co-administered with the MCB domain fusion protein. The dosage level of the MCB domain fusion protein can be up to the maximum tolerated dose (MTD) determined clinically or below the level of the MTD. The administration of the MCB domain fusion protein can be before, at the same time, or after the administration of the antibody. Treatment can include surgery as well as standard care treatment.

[0115] Various delivery systems can be used to administer therapeutic agents (including affected antibody agents, folate antimetabolites and / or platinum-based chemotherapy, MCB domain fusion proteins), including intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes, as required. The agent can be administered, for example, by infusion or bolus, via systemic or local routes, through absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.).

[0116] The therapeutic agent may be administered by injection via syringe, catheter, suppository, or any implantable matrix or device.

[0117] The therapeutic agents and pharmaceutical compositions thereof used as described herein can be orally administered in any acceptable dosage form, such as capsules, tablets, aqueous suspensions, solutions, and the like.

[0118] Suitable methods of administering the therapeutic agent include, but are not limited to, intravenous injection and intraperitoneal administration at a final concentration appropriate to be therapeutically effective.

[0119] The MCB domain fusion protein and other drugs can be administered in combination as a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the therapeutic agent and one or more pharmaceutically acceptable or compatible ingredients.

[0120] The amount of therapeutic agent effective in treating or preventing cancer or non-tumor diseases can be determined by standard clinical techniques. In addition, in vitro assays can be optionally used to help determine the optimal dosage range required for the MCB domain fusion protein. The effective dose can be extrapolated from the dose-response curve of the MCB domain fusion protein from an in vitro or animal model test system.

[0121] For example, LD can be determined by 50 (a dose lethal to 50% of the population) and ED 50 Standard pharmaceutical procedures determine the toxicity and therapeutic efficacy of a drug in cell cultures or experimental animals based on the value of the dose that is therapeutically effective in 50% of the population. The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD 50 / ED 50 Agents that exhibit large therapeutic indices are suitable. When an agent exhibits toxic side effects, a delivery system that targets the agent to the affected tissue site may be used to minimize potential damage to non-mesothelin expressing cells, thereby reducing side effects.

[0122] Administration and dosage regimens may vary depending on active drug concentration, which may depend on the needs of the subject.

[0123] Yet another embodiment labels the MCB domain fusion protein with a cytotoxic drug to specifically deliver the cytotoxin to target cells expressing CA125 in a patient expressing CA125.

[0124] Another embodiment labels an MCB domain fusion protein for detecting cells expressing CA125 for use in diagnostic applications to detect and / or monitor the status of cells expressing CA125 in vitro or in situ

[0125] Kit composition for optimizing the activity of MCB domain fusion protein

[0126] Also provided herein are kits for producing MCB domain fusion proteins suitable for overcoming the humoral immunosuppressive activity of CA125 against affected antibodies.

[0127] The kit may include an MCB domain fusion protein comprising two MCB domains connected by an amino acid spacer and genetically linked to the N-terminus of a human IgG1 Fc heavy chain domain anchor protein and an affected antibody, wherein the antibody may include but is not limited to rituximab.

[0128] The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples, which are provided for illustrative purposes only and are not intended to limit the scope of the present invention.

[0129] Example 1 - Schematic representation of MCB domain fusion proteins and their activity in overcoming humoral immune suppression by affected test antibodies.

[0130] Figure 1Schematic diagrams showing MCB domain fusion proteins, including: two MCB domains genetically linked and genetically fused to ankyrin via an amino acid spacer (A); three or more MCB domains genetically linked and fused to the N-terminal or C-terminal domain of ankyrin via an amino acid spacer (B); two MCB domains genetically linked and genetically fused to a human IgG1 Fc heavy chain domain via an amino acid spacer (C); three or more MCB domains genetically linked and fused to the N-terminal and C-terminal domains of ankyrin via an amino acid spacer (D). Ankyrin consists of a protein of 60 kDa or greater that exists as a monomer or a protein of 30 kDa or greater that exists as a multimer (dimer or higher order structure) to maintain a significant molecular weight to avoid renal excretion and a short serum half-life. In the case of HSA, although the connection can be at the N or C terminus, it can also be connected to an internal free cysteine ​​(referred to as Cys34 in some references) that has been used for conjugation of other molecules and is used by those skilled in the art (Sugio S, et al. Protein Engineering 12: 439–446, 1999). Alternatively, chemical modifications such as, but not limited to, pegylation can be used with smaller anchor proteins or multimers of the MCB domain itself to produce high molecular weight fusion proteins. The linked MCB domains shown here are attached by genetic linkage using a spacer unit GGGGC. The spacer units used include the use of a single spacer unit and a fusion protein comprising multiple spacer units.

[0131] Here, we provide two examples of MCB domain fusion proteins; one consisting of a single MCB domain (MCB domain-1X) linked to the N-terminus of a human Fc heavy chain (SEQ ID NO: 4), and the other consisting of two MCB domains (MCB domain-2X) domains linked to the N-terminus of a human Fc heavy chain (SEQ ID NO: 2) via a single spacer unit, whereby the Fc anchor retains a disulfide bridge. To generate a stable recombinant MCB domain fusion producing cell line, a commercial pCMV-IRES-zeocin vector was used. The cDNA encoding the MCB domain fusion protein was synthetically synthesized and cloned downstream of the CMV promoter and upstream of the IRES-zeocin resistance gene cassette. To generate a stable recombinant fusion protein producing cell line, FreeStyle 100 was maintained in serum-free HEK293 BalanCD medium (Irvine Scientific) containing 4 mM glutamine, 100 U / mL penicillin and 100 μg / mL streptomycin. TM 293-F cells (Thermo Fisher Scientific) were cultured at 0.5×10 6 / mL was inoculated in 4mL in a T25 vented capped flask. The cells were grown at 37°C and 5% CO2 with 70% humidity and shaking at 130RPM. The next day, 0.2mL of OptiPRO TM SFM (Thermo Fisher Scientific), 2 μg / each plasmid DNA and 15 μL polyethyleneimine (Max Mw 40,000) (Polysciences) were used for transfection reaction and incubated for 30 minutes before adding to the cells. The culture was grown for 48 hours at 130RPM shaking at 70% humidity and 37°C and 5% CO2. The cells were then plated in 10 cm culture dishes containing 10 mL / each RPMI 1640 (CaissonLabs), supplemented with 2 mM glutamine, 100 U / mL penicillin, 100 μg / mL streptomycin, 7.5% fetal bovine serum, and selected for 10 days in 200 μg / mL bleomycin (Thermo Fisher Scientific). Next, the cells were subcloned by limiting dilution and the recombinant MCB domain fusion protein production of the conditioned medium was tested after 2 weeks. The production subclones were expanded and adapted in serum-free HEK293 BalanCD medium containing 4 mM glutamine, 100 U / mL penicillin, 100 μg / mL streptomycin and 200 μg / mL bleomycin. The adapted culture was then expanded to 80 mL and grown for 7 days, at which time the culture was harvested and the MCB domain fusion protein was purified using protein A column affinity chromatography after dialysis in PBS buffer. The fusion protein was then quantified, diluted to equimolar volumes, and tested for its ability to overcome the CA125 humoral immunosuppression of the affected test antibody in a number of functional assays as described below.

[0132] Although previous reports have shown the ability of a single MCB domain fused to ankyrin to bind CA125, the ability of a specific MCB domain fusion configuration to overcome the humoral immune suppression of CA125 against the affected antibody has not been reported. As shown in Figure 2, the MCB domain fusion protein containing two MCB domains (MCB domain-2X) domains binds CA125 better than the fusion protein containing only one MCB domain (MCB domain-1X). This effect was recapitulated in the CD16a and C1q antibody binding ELISA, which showed that the MCB domain-2X fusion protein was able to significantly enhance the binding of CD16a as well as C1q to the affected test antibody in the presence of CA125 (Figure 3). Furthermore and unexpectedly, in a functional assay, when the affected antibodies (rituximab for CDC assay and NAV-007, a humanized anti-glycoprotein antibody for ADCC assay) were incubated with target cells and soluble CA125 or target cells naturally expressing CA125 were exogenously added in the presence of MCB domain-2X domain Fc fusion protein (SEQ ID NO: 2) and MCB domain-1X domain Fc fusion protein (SEQ ID NO: 4), only the MCB domain-2X fusion protein showed significantly enhanced humoral CDC ( Figure 4A ) and ADCC( Figure 4B ) activity (Figure 4). Consistent with the CA125 ELISA binding data, surface plasmon resonance (SPR) analysis by BiaCore revealed that compared with MCB domain-1X (KD = 6.52X10 -11 M), MCB domain-2X fusion protein has better binding affinity with CA125 (KD = 1.49X10 -11 M), which could explain this unexpected finding ( Figure 5 Together, these data suggest the need for the use of fusion proteins comprising at least two MCB domains to fully overcome the immunosuppression of ADCC and CDC humoral immune responses by CA125.

[0133] Example 2 - MCB domain fusion proteins having two or more MCB domains improve internalization and killing of CA125-expressing cells by antibody drug conjugates (ADCs).

[0134] along with and With the successful commercialization of, the use of antibody drug conjugates (ADC) has been growing for many years (Hedrich WD, et al. Clin Pharmacokinet 57: 687-703, 2018). The main mechanism by which these ADCs work is to target the cell surface antigens of cancer cells with antigen-specific antibody components, which bind and then internalize, where the cytotoxic payload is released from the antibody by internal proteolytic enzymes. The internalization rate can have a serious impact on the efficacy of a given ADC (Chalouni C and Doll SJ Exp Clin Cancer Res 37: 20-32, 2018). Here, we teach that CA125 can have a significant impact on the efficacy of ADCs against cancer cells that produce CA125. Figure 6 An example of how the cytotoxicity of an ADC can be reduced when treating tumor cells expressing high levels of CA125 is shown. In these studies, an anti-mesothelin ADC containing the topoisomerase inhibitor SN38 was used to combat the human ovarian cancer cell line OVCAR3 expressing mesothelin and CA125, as well as an engineered isogenic cell line (referred to as OVCAR-KO) that knocked down CA125 using shRNA (Sigma-Aldrich). Compared to parental OVCAR cells, similar lines have previously been published and shown to significantly enhance antibody-mediated humoral responses through antibodies affected by CA125 (Kline JB, et al. OncoTarget 8:52045-52060, 2017; Nicolaides NC, et al. Cancer Biol Ther 13:1-22, 2018). Figure 6 As shown in the bar graph on the left, the anti-mesothelin ADC was less effective in killing the OVCAR3 parental cell line compared to the isogenic OVCAR-KO line. To determine the use of MCB domain fusion proteins to enhance ADC killing of CA125-expressing tumor cells and antibodies affected by CA125, we plated OVCAR3 cells in a 96-well format and treated OVCAR3 parental cells with anti-mesothelin ADCs in the presence or absence of MCB domain-2X fusion protein (SEQ ID NO: 2). Figure 6 As shown in the bar graph on the right, administration of the MCB domain-2X fusion protein with ADC significantly enhanced ADC killing compared to cells treated with ADC alone.

[0135] Since internalization is a key factor in the cytotoxic activity of ADCs, we used Red Avidin (ThermoFisher) fluorescent pH sensor dye system, which can monitor the cellular uptake of antibodies. Briefly, OVCAR3 and OVCAR-KO cells were incubated with pHrodo-labeled anti-mesothelin antibody and pHrodo-labeled nonspecific antibody, prepared according to the manufacturer's instructions, and tested for uptake by OVCAR3 alone or in the presence of a fusion protein containing two MCB domains (MCB domain-2X) (SEQ ID NO: 2). Figure 7 As shown, OVCAR-KO cells had 35% higher uptake of anti-mesothelin antibodies compared to parental OVCAR3 cells (P<0.014). When OVCAR3 cells were pre-incubated with MCB domain-2X fusion protein for 1 hour and then tested for anti-mesothelin antibody uptake, the cells had 20% higher uptake than OVCAR3 cells not treated with MCB domain-2X fusion protein (P<0.018). There was almost no uptake of pHrodo-labeled control antibody (control-Ab), whose antigen is not expressed by OVCAR cells. Together, these data suggest that CA125 can affect the uptake and efficacy of ADC-based therapies, and that the use of MCB domain fusion proteins containing at least two MCB domains is sufficient to increase antibody uptake, making the ADC more cytotoxic to cells expressing CA125.

[0136] Table 1. Sequence identification (all sequences N to C terminus)

[0137] Italics indicate leader sequences

[0138] Bold indicates the smallest domain of the MCB domain

[0139] Underline Denotes amino acid spacer

[0140] Normal font indicates human Fc heavy chain domain

[0141] Italic Underline Represents the disulfide bridge portion of the Fc domain

[0142] SEQ ID NO:1

[0143]

[0144] SEQ IN NO:2

[0145]

[0146] SEQ IN NO:3

[0147]

[0148] SEQ ID NO:4

[0149] Sequence Listing <110> N. Nicolaides L. Grasso JB Klein <120> Compositions and uses of humoral immunosuppression antagonists for treating humoral immunosuppression diseases <130> 008966.00003 <160> 15 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 64 <212> PRT <213> Homo sapiens <400> 1 Glu Val Glu Lys Thr Ala Cys Pro Ser Gly Lys Lys Ala Arg Glu Ile 1 5 10 15 Asp Glu Ser Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu Ala Cys Val 20 25 30 Asp Ala Ala Leu Leu Ala Thr Gln Met Asp Arg Val Asn Ala Ile Pro 35 40 45 Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu Asp Glu Leu 50 55 60 <210> 2 <211> 384 <212> PRT <213> Homo sapiens <400> 2 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Glu Val Glu Lys Thr Ala Cys Pro Ser Gly Lys Lys Ala 20 25 30 Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu 35 40 45 Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln Met Asp Arg Val Asn 50 55 60 Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu 65 70 75 80 Asp Glu Leu Gly Gly Gly Gly Ser Glu Val Glu Lys Thr Ala Cys Pro 85 90 95 Ser Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys 100 105 110 Lys Trp Glu Leu Glu Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln 115 120 125 Met Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val 130 135 140 Leu Lys His Lys Leu Asp Glu Leu Glu Pro Lys Ser Cys Asp Lys Thr 145 150 155 160 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 165 170 175 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 180 185 190 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 195 200 205 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 210 215 220 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 225 230 235 240 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 245 250 255 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 260 265 270 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 275 280 285 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 290 295 300 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 305 310 315 320 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 325 330 335 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 340 345 350 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 355 360 365 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 370 375 380 <210> 3 <211> 453 <212> PRT <213> Homo sapiens <400> 3 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Glu Val Glu Lys Thr Ala Cys Pro Ser Gly Lys Lys Ala 20 25 30 Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu 35 40 45 Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln Met Asp Arg Val Asn 50 55 60 Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu 65 70 75 80 Asp Glu Leu Gly Gly Gly Gly Ser Glu Val Glu Lys Thr Ala Cys Pro 85 90 95 Ser Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys 100 105 110 Lys Trp Glu Leu Glu Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln 115 120 125 Met Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val 130 135 140 Leu Lys His Lys Leu Asp Glu Leu Gly Gly Gly Gly Ser Glu Val Glu 145 150 155 160 Lys Thr Ala Cys Pro Ser Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser 165 170 175 Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu Ala Cys Val Asp Ala Ala 180 185 190 Leu Leu Ala Thr Gln Met Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr 195 200 205 Glu Gln Leu Asp Val Leu Lys His Lys Leu Asp Glu Leu Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 4 <211> 315 <212> PRT <213> Homo sapiens <400> 4 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Glu Val Glu Lys Thr Ala Cys Pro Ser Gly Lys Lys Ala 20 25 30 Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu 35 40 45 Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln Met Asp Arg Val Asn 50 55 60 Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu 65 70 75 80 Asp Glu Leu Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 85 90 95 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 100 105 110 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 115 120 125 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 130 135 140 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 145 150 155 160 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 165 170 175 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 180 185 190 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 195 200 205 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 210 215 220 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 225 230 235 240 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 245 250 255 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 260 265 270 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 275 280 285 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 290 295 300 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 305 310 315 <210> 5 <211> 8 <212> PRT <213> Homo sapiens <400> 5 Gly Tyr Thr Phe Thr Ser Tyr Asn 1 5 <210> 6 <211> 8 <212> PRT <213> Homo sapiens <400> 6 Ile Tyr Pro Gly Asn Gly Asp Thr 1 5 <210> 7 <211> 14 <212> PRT <213> Homo sapiens <400> 7 Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val 1 5 10 <210> 8 <211> 6 <212> PRT <213> Homo sapiens <400> 8 Ser Ser Ser Val Ser Tyr 1 5 <210> 9 <211> 3 <212> PRT <213> Homo sapiens <400> 9 Ala Thr Ser 1 <210> 10 <211> 9 <212> PRT <213> Homo sapiens <400> 10 Gln Gln Trp Thr Ser Asn Pro Pro Thr 1 5 <210> 11 <211> 1155 <212> DNA <213> Homo sapiens <400> 11 atggggtggt catgtatcat cttgtttctc gtggccaccg cgactggcgt gcattcagag 60 gtggagaaga ccgcctgtcc gagcgggaaa aaggctcgcg agattgatga gtcactgatt 120 ttctacaaaa agtgggaact cgaggcttgc gtagatgcag ctcttctggc tactcaaatg 180 gacagagtaa atgctattcc ttttacttat gaacaattgg acgtattgaa acacaagctg 240 gatgaattgg gaggcggggg gtccgaggtc gagaagacgg cctgtccctc tggaaaaaaa 300 gcaagggaaa ttgacgagag tttgattttc tataagaaat gggagctcga agcatgtgta 360 gatgccgcac tgttggcaac tcaaatggat agggtgaacg caattccctt cacatatgaa 420 caactggatg tacttaagca taagttggac gaattggaac cgaaatcttg tgacaaaacg 480 catacatgtc cgccgtgccc ggcccccgag ctgctggggg gtcctagtgt cttctcttt 540 ccacctaagc ctaaggatac tctcatgatc tctcgcacac ccgaggtgac atgcgtagtc 600 gtggatgtca gccacgagga tccggaagtt aagtttaact ggtacgtcga cggagttgag 660 gtacacaatg cgaaaacaaa accacgcgag gaacagtata attccacgta ccgagtcgtt 720 tctgttctta cagtgttgca tcaggactgg ttgaatggaa aagaatataa atgcaaggtt 780 tcaaacaagg cactgccggc ccccatcgag aagactataa gcaaagccaa agggcaaccc 840 cgcgaaccac aagtctatac gctccctcca agtcgcgacg aacttaccaa aaaccaggtg 900 tcattgacct gtttggtgaa aggcttttat cccagcgaca tcgcggtgga atgggagtct 960 aacggtcaac ctgagaataa ctacaagact actcctcctg tattggactc tgatggatct 1020 ttttttctct attccaaact gacagttgat aagtctaggt ggcagcaagg gaatgtcttt 1080 agttgtagcg tgatgcatga agcattgcat aaccactata ctcaaaagtc cctgagcttg 1140 tccccgggga agtga 1155 <210> 12 <211> 384 <212> PRT <213> Homo sapiens <400> 12 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Glu Val Glu Lys Thr Ala Cys Pro Ser Gly Lys Lys Ala 20 25 30 Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu 35 40 45 Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln Met Asp Arg Val Asn 50 55 60 Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu 65 70 75 80 Asp Glu Leu Gly Gly Gly Gly Ser Glu Val Glu Lys Thr Ala Cys Pro 85 90 95 Ser Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys 100 105 110 Lys Trp Glu Leu Glu Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln 115 120 125 Met Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val 130 135 140 Leu Lys His Lys Leu Asp Glu Leu Glu Pro Lys Ser Cys Asp Lys Thr 145 150 155 160 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 165 170 175 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 180 185 190 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 195 200 205 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 210 215 220 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 225 230 235 240 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 245 250 255 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 260 265 270 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 275 280 285 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 290 295 300 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 305 310 315 320 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 325 330 335 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 340 345 350 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 355 360 365 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 370 375 380 <210> 13 <211> 1362 <212> DNA <213> Homo sapiens <400> 13 atggggtggt catgtatcat cttgtttctc gtggccaccg cgactggcgt gcattcagag 60 gtggagaaga ccgcctgtcc gagcgggaaa aaggctcgcg agattgatga gtcactgatt 120 ttctacaaaa agtgggaact cgaggcttgc gtagatgcag ctcttctggc tactcaaatg 180 240. gacagagtaa atgctattcc ttttacttat gacaattgg acgtattgaa acacaagctg gatgaattgg gaggcggggg gtccgaggtc gagagacgg cctgtccctc tggaaaaaaa gcaagggaaa ttgacgagag tttgattttc tataagaaat gggagctcga agcatgtgta gatgccgcac tgttggcaac tcaaatggat agggtgaacg caattccctt cacatatgaa caactggatg tacttaagca taagttggac gaattggggag gcggggggtc cgaggtcgag aagacggcct gtccctctgg aaaaaaagca agggaaattg acgagagttt gattttctat 540 aagaaatggg agctcgaagc atgtgtagt gccgcactgt tggcaactca aatggatagg gtgacgca ttcccttcac atatgaca ctggatgtac ttagcata gttggacga ttggaaccga aatcttgtga caaaacgcat acatgtccgc cgtgcccggc ccccgagctg ctggggggtc ctagtgtctt tctctttcca cctaagccta aggatactct catgatctct 780 cgcacacccg aggtgacatg cgtagtcgtg gatgtcagcc acgaggatcc ggaagttaag tttaactggt acgtcgacgg agttgaggt cacaatgcga aaacaaaacc acgcgagga cagtataatt ccacgtaccg agtcgtttct gttcttacag tgttgcatca ggactggttg 960 aatggaaaag aatataaatg caaggtttca aacaaggcac tgccggcccc catcgagaag 1020 actataagca aagccaaagg gcaaccccgc gaaccacaag tctatacgct ccctccaagt 1080 cgcgacgaac ttaccaaaaa ccaggtgtca ttgacctgtt tggtgaaagg cttttatccc 1140 agcgacatcg cggtggaatg ggagtctaac ggtcaacctg agaataacta caagactact 1200 cctcctgtat tggactctga tggatctttt tttctctatt ccaaactgac agttgataag 1260 tctaggtggc agcaagggaa tgtctttagt tgtagcgtga tgcatgaagc attgcataac 1320 cactatactc aaaagtccct gagcttgtcc ccggggaagt ga 1362 <210> 14 <211> 453 <212> PRT <213> Homo sapiens <400> 14 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Glu Val Glu Lys Thr Ala Cys Pro Ser Gly Lys Lys Ala 20 25 30 Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu 35 40 45 Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln Met Asp Arg Val Asn 50 55 60 Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu 65 70 75 80 Asp Glu Leu Gly Gly Gly Gly Ser Glu Val Glu Lys Thr Ala Cys Pro 85 90 95 Ser Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys 100 105 110 Lys Trp Glu Leu Glu Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln 115 120 125 Met Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val 130 135 140 Leu Lys His Lys Leu Asp Glu Leu Gly Gly Gly Gly Ser Glu Val Glu 145 150 155 160 Lys Thr Ala Cys Pro Ser Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser 165 170 175 Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu Ala Cys Val Asp Ala Ala 180 185 190 Leu Leu Ala Thr Gln Met Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr 195 200 205 Glu Gln Leu Asp Val Leu Lys His Lys Leu Asp Glu Leu Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 15 <211> 5 <212> PRT <213> Homo sapiens <400> 15 Gly Gly Gly Gly Ser 1 5

Claims

1. A fusion protein, which is a polypeptide comprising: (a) at least two copies of the minimal CA125 binding domain of mesothelin as shown in SEQ ID NO: 1, wherein the at least two copies of the minimal CA125 binding domain are connected by a spacer unit comprising one or more GGGGS (SEQ ID NO: 15) units, and (b) an ankyrin, which is a heavy chain Fc domain of a human IgG1 isotype antibody, wherein the at least two copies of the minimal CA125 binding domain are at the N-terminus of the ankyrin.

2. The fusion protein of claim 1, wherein the heavy chain Fc domain comprises a disulfide bridge. 3 . The fusion protein of claim 1 , wherein the ankyrin is linked to at least one copy of the minimal CA125 binding domain via a disulfide bridge. The fusion protein according to claim 1 , wherein the sequence of the fusion protein is shown in SEQ ID NO:

2. The fusion protein according to claim 1 , wherein the sequence of the fusion protein is shown in SEQ ID NO:

3. The fusion protein of claim 1 , wherein the fusion protein binds CA125 with an affinity greater than KD=65 pM.

7. The fusion protein of claim 1, wherein the fusion protein binds CA125 with an affinity greater than KD=50 pM.

8. The fusion protein of claim 1, wherein the fusion protein binds CA125 with an affinity greater than KD=25 pM.

9. A nucleic acid vector encoding the fusion protein of claim 1.

10. A nucleic acid vector encoding the fusion protein of claim 4.

11. A nucleic acid vector encoding the fusion protein of claim 5.

12. A stable cell line encoding the fusion protein of claim 1.

13. A stable cell line encoding the fusion protein of claim 4.

14. A stable cell line encoding the fusion protein of claim 5.

15. Use of the fusion protein and antibody-drug conjugate according to claim 1 in the preparation of a drug combination for treating cancer patients, wherein the patients express elevated levels of CA125 compared to healthy people, wherein the antibody-drug conjugate targets tumors, and wherein the humoral immune response mediated by the antibody in the absence of the fusion protein is inhibited by CA125.

16. The use according to claim 15, wherein the disease is ovarian cancer.

17. The use according to claim 15, wherein the disease is a cancer selected from the group consisting of mesothelioma, breast cancer, lung cancer, colorectal cancer, gastrointestinal cancer, endometrial cancer and pancreatic cancer.

18. The use according to claim 15, wherein the fusion protein is attached to a cytotoxic drug.

19. The use according to claim 15, wherein the fusion protein is attached to a radionuclide.

20. Use of the fusion protein according to claim 1 in the preparation of a reagent or a kit for monitoring a tumor expressing CA125 in a patient, wherein the monitoring comprises: contacting a body fluid sample from the patient with the fusion protein of claim 1; and CA125 bound to the fusion protein is detected.

21. Use of the fusion protein according to claim 1 in preparing a reagent or a kit for monitoring a tumor expressing CA125 in a patient, Wherein the fusion protein is detectably labeled.

Citation Information

Patent Citations

  • Anti-MUC16 antibodies and uses thereof

    CN107667120A

  • Blocking mesothelin peptide fragments

    US8623828B2